Markets by TradingView

Browsing Tag

orphan drug

10 posts

Cardiol Therapeutics Achieves Phase III MAVERIC Enrollment Target Ahead of Schedule and Expands Pivotal Trial to Strengthen Assessment of CardiolRx™’s Efficacy; Analysts Reiterate Buy Ratings

An incredible amount of planning and preparation goes into the design of…

Cardiol Therapeutics: Analysts and Institutions Are In

Ahead of the pivotal Phase III MAVERIC topline results, expected in mid-2027,…

Small Pharma, Big Gains: The Power of Clinical Trial Results

For smaller pharmaceutical companies, valuation can be greatly impacted by progression in…

Cardiol Therapeutics Completes Patient Enrollment in its Phase II MAvERIC-Pilot Study Investigating CardiolRx(TM) for Recurrent Pericarditis

Topline Results Expected in Q2 2024 This is a Designated News Release.…

Cardiol Therapeutics Granted Orphan Drug Designation for its Lead Drug Candidate for the Treatment of Pericarditis

Designation Based on Pre-Clinical Data and Initial Clinical Data from the Company’s…